The Patent Finder

Terms ending in 2035

Acceleron Pharma Inc.

Every in-force patent on Acceleron Pharma Inc.'s record whose computed term ends in 2035, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresConfidence
US 10,010,498Methods for Treatment of Amyotrophic Lateral Sclerosis with Follistatin Fusion Proteins
In force
 · High confidence
Acceleron Pharma Inc.In forceHigh confidence
US 10,023,621Follistatin-Related Fusion Proteins
In force
 · High confidence
Acceleron Pharma Inc.In forceHigh confidence
US 11,497,792Methods for Treatment of Duchenne Muscular Dystrophy with Follistatin Polypeptides
In force
 · Medium confidence
Acceleron Pharma Inc.In forceMedium confidence
US 9,850,298Methods for Treating Ulcers in Thalassemia Syndrome with an Actriib Polypeptide
In force
 · High confidence
Acceleron Pharma Inc.In forceHigh confidence
US 10,487,144Methods for Treating Ulcers in a Hemoglobinopathy Anemia with a Soluble Actriib Polypeptide
In force
 · High confidence
Acceleron Pharma Inc.In forceHigh confidence
US 11,260,107Methods and Compositions for Treating Ulcers
In force
 · High confidence
Acceleron Pharma Inc.In forceHigh confidence
US 10,765,626Methods for Treatment of Charcot-Marie-Tooth Disease with Follistatin Polypeptides
In force
 · Medium confidence
Acceleron Pharma Inc.In forceMedium confidence
US 10,954,279Methods and Compositions for Treatment of Disorders with Follistatin Polypeptides
In force
 · Medium confidence
Acceleron Pharma Inc.In forceMedium confidence
US 10,603,359Methods and Compositions Using GDF15 Polypeptides for Increasing Red Blood Cells
In force
 · High confidence
Suragani, Rajasekhar Naga Venkata SaiIn forceHigh confidence
US 11,642,394Methods and Compositions Using GDF15 Polypeptides for Increasing Red Blood Cells
In force
 · Medium confidence
Suragani, Rajasekhar Naga Venkata SaiIn forceMedium confidence
2 more term ends in 2035 · Pro
10 of 12 patents shown. Soonest term end first, then patent number.
Pro members see all 12.
Upgrade to Pro
10 of these are in force and held by Acceleron Pharma Inc..
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited